Shamburg News · 8-K filed Oct 26, 2026, 4:40 PM EDT

Cumberland Pharmaceuticals Plans NDA Submission for Ifetroban in DMD Cardiomyopathy

CPIX · CUMBERLAND PHARMACEUTICALS INC

  • Other event
  • Reg FD disclosure
  • Materiality: medium

On October 26, 2026, Cumberland Pharmaceuticals Inc. announced plans to submit a New Drug Application to the FDA for ifetroban as a treatment for cardiomyopathy associated with Duchenne muscular dystrophy. The company said the submission will rely on the FIGHT DMD Phase 2 trial and natural history data, and that the FDA granted a rolling review of the NDA following a pre-NDA meeting. The filing states there can be no assurance the FDA will accept the NDA or approve ifetroban.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 7.01, 8.01, accession 0001087294-26-000072.

Written from the filing by Shamburg Markets. Figures are as reported by the company.